Abingdon Health (LSE:ABDX) has been awarded contracts worth about £4.8m by a U.S.-based customer to develop and scale multiple multiplex quantitative lateral flow assay systems capable of detecting several biomarkers within human samples. The project will run for 27 months and will begin immediately. It covers full programme oversight, regulatory process management, and both analytical and clinical performance services, delivered through milestone-based work packages that could expand further as the programme progresses.
The contracts will be executed across Abingdon’s sites in York and Madison, drawing on the expertise of its regulatory businesses CS Lifesciences and IVDeology, alongside analytical and performance testing support from Abingdon Analytical in Doncaster. The agreement strengthens the company’s role as an integrated CDMO and CRO partner for the development and manufacture of lateral flow diagnostics, enhancing its commercial pipeline while highlighting demand for its end-to-end service offering among international med-tech clients.
The company’s outlook reflects mixed financial signals. While revenue growth has been strong, profitability and cash flow remain under pressure. Technical indicators point to a largely neutral share price trend without strong momentum. Valuation metrics are also relatively weak due to a negative price-to-earnings ratio and the absence of a dividend yield, resulting in a broadly moderate overall assessment.
More about Abingdon Health PLC
Abingdon Health plc is a UK-based med-tech contract service provider focused on rapid diagnostic technologies. The company operates as a contract development and manufacturing organisation (CDMO), delivering services that include lateral flow assay development, regulatory support, technology transfer and manufacturing. Its solutions support a range of markets, including infectious diseases, clinical and companion diagnostics, animal health and environmental testing across global markets.
Leave a Reply